GuidelineBreast (Edinburgh, Scotland)2024
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).
Registry-linked trialAbstract readPractice Guideline
In one paragraph
Guideline in Breast (Edinburgh, Scotland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07753954 (Imaging to Re-evaluate Elacestrant Clinical Application), which is not on this map. Cited by 154 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07753954 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Imaging to Re-evaluate Elacestrant Clinical Application
Who cites it
154 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.Breast (Edinburgh, Scotland) · 2026Pooled it
- Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC).Current oncology (Toronto, Ont.) · 2026Guideline
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature review.Breast (Edinburgh, Scotland) · 2025Pooled it
- [Systemic treatment of breast cancer: professional guideline].Magyar onkologia · 2025Guideline
- Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.Breast cancer research : BCR · 2025Pooled it
- Effect of locoregional surgery in primary tumors on overall survival in patients withFrontiers in oncology · 2025Pooled it
- Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.Breast (Edinburgh, Scotland) · 2026Trial
- Trial
- Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study.Breast cancer research : BCR · 2026Trial
- Trial
- Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women.Clinical and translational science · 2026Trial
- Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study.BMC medicine · 2026Trial
- Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.Breast cancer research : BCR · 2025Trial
- Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.Breast cancer research and treatment · 2025Trial
- A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial.Breast cancer research and treatment · 2025Trial
- Overall Survival with Inavolisib inThe New England journal of medicine · 2025Trial
- Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.JCO precision oncology · 2025Trial
- Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.Breast cancer (Tokyo, Japan) · 2025Trial
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors.
Fatima CardosoBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, and ABC Global Alliance, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
Shani Paluch-ShimonHadassah University Hospital - Sharett Institute of Oncology, Jerusalem, Israel.
Eva Schumacher-WulfMamma Mia, Kronberg, Germany.
Leonor MatosBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Karen GelmonBC Cancer Agency, Department of Medical Oncology, Vancouver, Canada.
Matti S AaproCancer Center, Clinique de Genolier, Genolier, Switzerland.
Jyoti BajpaiTata Memorial Centre, HBNI, Mumbai, India.
Carlos H BarriosLatin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil.
Jonas BerghDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Elizabeth Bergsten-NordströmEuropa Donna - the European Breast Cancer Coalition, Norrkoping, Sweden.
Laura BiganzoliDepartment of Oncology, Hospital of Prato - Azienda USL Toscana Centro Prato, Italy and European Society of Breast Cancer Specialists (EUSOMA), Italy.
Maria João CardosoBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation and Lisbon University, Faculty of Medicine, Lisbon, Portugal.
Lisa A CareyUNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
Mariana Chavez-MacGregorHealth Services Research, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, USA and American Society of Clinical Oncology (ASCO), Houston, USA.
Runcie ChidebeProject PINKBLUE, Abuja, Nigeria.
Javier CortésInternational Breast Cancer Center (IBCC), Madrid and Barcelona, Spain.
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
Rebecca A DentNational Cancer Center Singapore, Singapore, Singapore.
Nagi S El SaghirNK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Alexandru EniuHôpital Riviera-Chablais, Vaud-Valais Rennaz, Switzerland and European School of Oncology (ESO), United Kingdom.
Lesley FallowfieldBrighton & Sussex Medical School, University of Sussex, Brighton, United Kingdom.
Prudence A FrancisDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.
Sandra X Franco MillanCTIC, Cancer Treatment and Research Center, Bogotá, Colombia.
Jenny GilchristMacquarie University, Sydney, Australia.
Joseph GligorovDepartment of Medical Oncology, Cancer Est APHP Tenon, University Paris VI, Nice/St Paul Guidelines, Paris, France.
William J GradisharNorthwestern Medicine, Illinois, USA and National Comprehensive Cancer Network (NCCN), USA.
Renate HaidingerBrustkrebs Deutschland e.V., Munich, Germany.
Nadia HarbeckBreast Centre, University of Munich, Munich and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ranjit KaurBreast Cancer Welfare Association, Petaling Jaya, Malaysia.
Belinda KielyNHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia.
Sung-Bae KimAsan Medical Centre, Department of Oncology, Seoul, South Korea.
Smruti KoppikarLilavati Hospital and Research Centre, Bombay Hospital Institute of Medical Sciences, Asian Cancer Institute, Mumbai, India.
Marion J J Kuper-HommelTe Whatu Ora Waikato, Midland Regional Cancer Centre, NZ ABC Guidelines, Hamilton, New Zealand.
Frédéric E LecouvetDepartment of Radiology, Institut Roi Albert II and Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium.
Ginny MasonInflammatory Breast Cancer Research Foundation, West Lafayette, USA.
Shirley A MertzMBC US Alliance and Metastatic Breast Cancer Network US, Inverness, USA.
Volkmar MuellerUniversity Medical Center Hamburg-Eppendorf, Hamburg and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany.
Claire MyersonBreast Cancer Now, London, United Kingdom.
Silvia NeciosupDepartment of Medical Oncology, National Institute of Neoplastic Diseases, Lima, ABC Latin America Guidelines, Peru.
Birgitte V OffersenDepartment of Oncology, Aarhus University Hospital, Aarhus, European Society for Radiotherapy and Oncology (ESTRO), Denmark.
Shinji OhnoBreast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan.
Olivia PaganiHôpital Riviera-Chablais, Vaud-Valais Rennaz, Switzerland.
Ann H PartridgeDana-Farber Cancer Institute, Department of Medical Oncology and Division of Breast Oncology, Boston, USA and American Society of Clinical Oncology (ASCO), USA.
Frédérique Penault-LlorcaCentre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000, Clermont Ferrand, Nice/St Paul Guidelines, France.
Aleix PratHospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.
Hope S RugoBreast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
Elzbieta SenkusDepartment of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
George W SledgeDivision of Oncology, Stanford School of Medicine, Stanford, USA.
Sandra M SwainGeorgetown University Lombardi Comprehensive Cancer Center and MedStar Health, Washington DC, USA.
Christoph ThomssenDepartment of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale) and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany.
Daniel A VorobiofBelong.Life, New York, USA.
Peter VuylstekeUniversity of Botswana, Gaborone, Botswana and CHU UCL Namur Hospital, UCLouvain, Belgium.
Theresa WisemanThe Royal Marsden NHS Foundation Trust, University of Southampton, United Kingdom and European Oncology Nursing Society (EONS), United Kingdom.
Binghe XuDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Alberto CostaEuropean School of Oncology, Milan, Italy and Bellinzona, Switzerland.
Larry NortonBreast Cancer Programs, Memorial Sloan-Kettering Cancer Centre, New York, USA.
Eric P WinerYale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Global Alliance. It provides the main recommendations on how to best manage patients with advanced breast cancer (inoperable locally advanced or metastatic), of all breast cancer subtypes, as well as palliative and supportive care. These guidelines are based on available evidence or on expert opinion when a higher level of evidence is lacking. Each guideline is accompanied by the level of evidence (LoE), grade of recommendation (GoR) and percentage of consensus reached at the consensus conferences. Updated diagnostic and treatment algorithms are also provided. The guidelines represent the best management options for patients living with ABC globally, assuming accessibility to all available therapies. Their adaptation (i.e. resource-stratified guidelines) is often needed in settings where access to care is limited.
Indexed as
Breast NeoplasmsPalliative CareConsensusFemaleHumansABCAdvancedBreast cancerConsensusGuidelinesMetastatic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07753954ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.